Welcome to our dedicated page for Algernon Health news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Health stock.
Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Algernon Health (OTCQB: AGNPF) announced that effective April 21, 2026 it will change its corporate name to Grey Matters Health Inc. and complete a 10:1 consolidation of its Class A common shares.
The company will begin trading under the new CSE symbol GREY, with new CUSIP 397884107 and ISIN CA3978841078. Post-consolidation issued and outstanding common shares will be approximately 5,418,243. Letters of transmittal will be mailed to registered shareholders; no action is required by non-registered shareholders. Outstanding preferred shares, warrants, stock options and restricted share units will be adjusted per their terms.
Algernon Health (OTCQB: AGNPF) plans to change its name to Grey Matters Health Inc. and reserved the CSE symbol GREY. The company proposes a 10:1 share consolidation, reducing 54,182,431 shares to ~5,418,243 post-consolidation.
The rebrand aligns with a shift toward Alzheimer’s diagnostic services and plans to open NovaScan Neuroimaging Clinics, with the first clinic announced at HCA Florida University Hospital in Davie. The company retains drug-development assets, including a 20% stake in Seyltx and intellectual property for DMT stroke and CKD programs. Name change and consolidation require CSE approval.
Algernon Health (OTCQB: AGNPF) unveiled NovaScan Neuroimaging Clinics as the brand for its planned U.S. brain PET network, launching at HCA Florida University Medical Offices in Davie, FL.
Clinics will feature the U.S. FDA-cleared CareMiBrain™ standalone PET scanner, offering dedicated brain imaging, 25% less radiation versus PET/CT, and support for dementia, epilepsy, Parkinson’s, MS, brain cancer and clinical trials. An official opening date and referral start will be announced soon.
Algernon Health (OTCQB: AGNPF) will open its first U.S. brain-dedicated PET scanning clinic on March 23, 2026, at the HCA Florida University Medical Office Building in Davie, Florida. Algernon USA signed a five-year lease with a renewal option and plans multiple U.S. clinics.
The clinic will use the U.S. FDA-cleared CareMiBrain™ standalone PET system (no integrated CT), which the company says reduces patient radiation by ~25%, and targets Alzheimer’s, dementia, epilepsy, neuro-oncology and movement disorders.
Algernon Health (OTCQB: AGNPF) announced a non-brokered private placement to raise gross proceeds of $500,000 by issuing Units at $0.07 per Unit. Each Unit includes one Class A common share and one-half warrant; full warrants initially exercisable at $0.15 for 12 months, then $0.25 (12 months), then $0.50 (36 months) with an acceleration clause tied to CSE trading.
Close expected in tranches on or before Nov 30, 2025. Proceeds directed to the Alzheimer’s program, opening a U.S. brain-specific neuroimaging clinic, G&A and working capital. The company also converted 1,268,334 subscription receipts into Series 1 preferred shares and issued related warrants; shareholders approved an unlimited preferred share structure on Sep 19, 2025.
Algernon Health (OTCQB: AGNPF) completed its name change from Algernon Pharmaceuticals and will begin trading under the new name on the CSE at market open on October 20, 2025 while retaining the same ticker symbol. The common shares received a new CUSIP 01559C106 and ISIN CA01559C1068; no shareholder action is required.
The company said it will focus on the Alzheimer’s disease diagnostic market by establishing neuroimaging clinics using U.S. FDA-cleared brain-specific PET scanners. Algernon signed a definitive equipment order and financing agreement with Catalyst MedTech for four CareMiBrain PET systems, a non-dilutive deal valued at > CDN $4 million, plus terms to acquire six additional systems on an adjusted-cost basis.
Catalyst MedTech launched the Connect program on October 7, 2025 to expand access to advanced diagnostic imaging by combining its Equipment Solutions and Clinical Solutions businesses.
As part of the launch Catalyst announced a first Connect partnership with Algernon Pharmaceuticals (OTCQB: AGNPF) to advance Optimized Brain PET imaging in the U.S. and establish a dedicated network of neuroimaging clinics for earlier detection of Alzheimer’s. Catalyst will supply a tailored mix of equipment, service, and support, featuring the CareMiBrain system plus the NeuroQ quantitative workstation.
Algernon Pharmaceuticals (OTCQB: AGNPF) has secured a CAD $4 million non-dilutive financing agreement with Catalyst MedTech to acquire four FDA-cleared Oncovision CareMiBrain™ brain-specific PET scanners. The deal includes financing terms with a 20% deposit and 7% annual interest rate, plus an option to acquire six additional systems for future expansion.
The company plans to establish the first dedicated brain-specific PET neuroimaging clinics in the U.S., focusing on early-stage Alzheimer's detection. Each scan will cost approximately US$5,000 and is covered by private insurance, Medicare, and Medicaid. The CareMiBrain™ system offers advanced features including 25% reduced radiation exposure compared to traditional PET/CT scanners and enhanced patient comfort.
Algernon Pharmaceuticals (OTCQB: AGNPF) announced that shareholders approved the creation of a new preferred share class at its annual and special meeting, with over 93% votes in favor. The Series 1 Preferred Shares will include a 10% annual dividend payable in Common or Preferred Shares and are convertible into 10 Common Shares each.
Following the approval, the Company will issue 450,000 Preferred Shares and Preferred Warrants related to a May 2025 acquisition, and 1,268,334 Preferred Shares and 634,167 Preferred Warrants from a July 2025 private placement. Additionally, all five board nominees were elected with over 95% approval. The company also plans to rebrand as Algernon Health Inc. to reflect its expansion into Alzheimer's Disease diagnostics and neuroimaging clinics across North America.
Algernon Pharmaceuticals (OTCQB: AGNPF) has announced its rebranding to Algernon Health, marking a strategic shift towards the Alzheimer's Disease (AD) diagnostic market. The company plans to establish specialized neuroimaging clinics across North America, featuring FDA-cleared brain-specific PET scanning systems that offer lower radiation exposure compared to standard PET/CT machines.
The company's clinics will provide essential amyloid plaque detection services required for FDA-approved AD treatments like Kisunla and Leqembi. These diagnostic services are covered by Medicare, Medicaid, and private insurance in the U.S. The clinics will also offer PET scans for other neurological conditions, including dementia, epilepsy, neuro-oncology, and movement disorders.
Algernon maintains its subsidiary Algernon NeuroScience, focused on DMT research for stroke and brain injury, and holds a 20% stake in Seyltx, which is developing a chronic cough drug.